All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Latest updates from the phase III QuANTUM-First trial
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2023 Congress, the AML Hub was pleased to speak to Harry Erba, Duke University, Durham, US. We asked, What are the latest updates from the phase III QuANTUM-First trial?
What are the latest updates from the phase III QuANTUM-First trial?
Erba discusses the QuANTUM-First trial (NCT02668653) assessing the addition of quizartinib vs placebo to standard chemotherapy and continuation therapy in adult patients aged 18–75 years with newly diagnosed FLT3-internal tandem duplication mutated acute myeloid leukemia. He continues by delving into response rates, survival outcomes, and safety data from the trial; outlining the factors that could influence responses. Erba compares the findings of QuANTUM-First with the phase III RATIFY trial (NCT00651261), which investigated the addition of midostaurin to standard chemotherapy in patients with FLT3-mutated AML.
Your opinion matters
28 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox